 |
 |
 |
 |
 |
NeuroTraq is developing Bio-signal Analysis Monitoring (BAM) technology to accurately characterize conditions like pain, stress, depression, or post traumatic stress disorder that medical technology currently cannot objectively monitor. Understanding such complex neurophysiological states requires concurrent multivariate assessment of many parameters, which the proprietary BAM processing methods make possible in near-real time.
BAM will accurately identify and depict complex neurophysiological conditions for clinicians, permitting efficient diagnoses and optimized medical protocols resulting in faster, safer, and better treatment outcomes. This will create important new paradigms for medical research, diagnosis and treatment in strategic clinical markets.
NeuroTraq is currently studying BAM methods to reveal hidden early stage cardiovascular (CV) problems. The objective is to detect CV issues when the treatment prognosis is more favorable and before sufficient damage occurs to make such conditions belatedly apparent to conventional monitoring methods.
BAM will accurately identify and depict complex neurophysiological conditions for clinicians, permitting efficient diagnoses and optimized medical protocols resulting in faster, safer, and better treatment outcomes. This will create important new paradigms for medical research, diagnosis and treatment in strategic clinical markets.
NeuroTraq is currently studying BAM methods to reveal hidden early stage cardiovascular (CV) problems. The objective is to detect CV issues when the treatment prognosis is more favorable and before sufficient damage occurs to make such conditions belatedly apparent to conventional monitoring methods.
BAM technology is protected by recent patents filed by NeuroTraq founder, John Bell.
The EASE Project
Introduction
BAM Technology
NeuroTraq is seeking experienced senior executives and a few talented staff to help take NeuroTraq to the next level:
Learn More
Learn More
Copyright 2006, NeuroTraq, Inc. All rights reserved.
NeuroTraq, EASE, the Neurotraq logo, and "New Paradigms in Clinical Technology" are trademarks of NeuroTraq, Incorporated.
EASE is an innovative medical technology development platform based on BAM Technology. The EASE platform consists of a technology triad of neurophysiological monitoring, bio-signal processing, and advanced neuromodulation.
Contact Information: John Bell, President
MCPC 320-F
9750 S 300W
Sandy, Utah 84070
80I-9I8-3478
MCPC 320-F
9750 S 300W
Sandy, Utah 84070
80I-9I8-3478
